NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned...

40
NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy

Transcript of NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned...

Page 1: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

NTRKinhibitors:whatwelearnedandwheretogoMichelaCasanova,FondazioneIRCCSIstitutoNazionaledeiTumoriMilano,Italy

Page 2: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

TRKreceptorsmediateneurotrophinsignaling•  Neurotrophinsareimportantgrowthfactorsinvolvedinthegrowth,differentiation,andsurvivalofneurons

•  NeurotrophinsignalingoccursthroughactivationoftheTRKreceptorfamily

NeurotrophinFamilyofReceptors

TRKReceptor

Gene(Chromosomal

Location)

FunctionsNaturalLigandsDevelopmental Adult

TRKA NTRK1(1q23.1)

Cellulardifferentiation/sensoryneuronsubtypespecificationanddevelopmentofpainandthermoregulationmodalities

Painsignaling,thermoregulation

Nervegrowthfactor(NGF),neurotrophin-3(NT-3)

TRKB NTRK2(9q21.33)

Developmentofsensoryneuronsinthebrain

Regulationofmovement,memory,mood,appetite,bodyweight

Brain-derivedneurotrophicfactor(BDNF),neurotrophin-3/4/5(NT-3/4/5)

TRKC NTRK3(15q25.3)

Neuronaldifferentiation,axonoutgrowth/guidance,andsynapticplasticity

Proprioception NT-3

NeurotrophinSignaling1,3

Page 3: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Genefusions:animportantclassofoncogenes•  Associatedwithadiverserangeofsolidtumoursand

hematologicmalignancies

•  NTRKgenefusionsareassociatedwithmanyhumancancers•  Associatedwith≥19tumourtypes

•  Implicatedinupto1%ofallsolidtumours

TRKfusionproteinsareprimaryoncogenicdrivers

Page 4: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

TRKfusioncanceroccursacrossawiderangeofchildhoodandadulttumourtypes

Paediatric/youngadult

InfantilefibrosarcomaThyroidcancer

Sarcoma(multiple)

Spitznevi

Adult

Thyroidcancer

IntrahepaticcholangiocarcinomaSecretorybreastcancer

SalivaryMASC

Braincancer(glioma,GBM,astrocytoma)

Lungcancer

Colon

Melanoma

Pancreatic

Sarcoma

Paediatric(infants)high-gradeglioma

Congenitalmesoblasticnephroma

•  RaretumourswithhighNTRKgenefusionfrequency

•  CommontumourswithlowNTRKgenefusionfrequency

GBM,glioblastomamultiforme;MASC,mammaryanaloguesecretorycarcinoma;NTRK,neurotrophictyrosinereceptorkinase;TRK,tropomyosinreceptorkinase.

Page 5: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Single-drivertumorsparticularlysuitable

forprecisionmedicine

10

Highunmetneedbothintermsofchanceofrelapsebutalsocurrenttherapiescanleadtosignificanttreatmentburdenandlongtermsideeffects

Whatwearelearning:braintumors

Page 6: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Whatwelearned:rapidclinicaldevelopment

Page 7: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

•  LarotrectinibisthefirstandonlyselectiveTRKinhibitor

•  HighlypotentagainstTRKA,TRKB,andTRKC

•  IC505–11nM•  Highlyselective

•  Limitedinhibitionofotherkinases

•  Noinhibitionof229otherkinasesat1000nM

•  DemonstrateactivityinCNSdisease

Larotrectinib

Page 8: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Larotrectinib

Page 9: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Larotrectinib

Page 10: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Larotrectinib

Whatwelearned:efficacy

Page 11: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Entrectinib

Page 12: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Entrectinib

Page 13: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

28childrentreatedbetween5/2016-10/2018

Page 14: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Entrectinib

Page 15: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Entrectinib/Larotrectinib Entrectinib ORR Larotrectinib ORR

Extra-CNS NTRK+ 3/3 (3 PR) 100% (29-100%)

32/34 (11 CR, 21 PR)

94% (80-99%)

CNS NTRK + 3/4 (1 CR, 2 PR, 1ong)

75% (19-100%)

5/11 (2 CR, 3 PR) 45% (17-77%)

CNS ROS1 + 2/2 (1 PR, 1 uPR)

Extra-CNS ROS1 + 1/1 (1 PR)

Extra-CNS ALK + Fusion: 2/2 (2 CR) Mut: 1/1 (1CR)

•  Differenceresponseratetoextra-CNSandCNStumorrelatedtoCNSpenetrance?•  LarotrectinibwasdesignedtohavelimitedCNSpenetrationtoreducethepotential

foron-targettoxicityduetoinhibitionofnormalTRKreceptorsinthebrain•  EntrectinibwasfirstdevelopedasanALKinhibitor

Page 16: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Larotrectinib

Page 17: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Larotrectinib

Page 18: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Larotrectinib

Page 19: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

PotentialNTRKinhibitorstoxicities

NodataonlateeffectsThephaseIadulttrialoflarotrectinibenrolledpatientstartinginMarch2015

Page 20: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Entrectinib

Page 21: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

NTRKinhibitorsapprovedinNTRK-fusionpositivetumours

Larotrectinib

Approved: FDA 2018; Brazil, Canada, EMA 2019

Dose: 25-mg or 100-mg oral capsule or 20-mg/mL oral solution

•  Adults and children with BSA ≥1.0m2: 100 mg orally BID

•  Children with BSA ≤1.0m2 : 100 mg/m2 orally BID

Entrectinib

Approved: FDA and Japan 2019

Dose: 100-mg and 200-mg oral capsule

•  Adults: 600 mg orally once daily

•  Children: Recommended dose based on BSA

Indication: For the treatment of patients with solid tumours harbouring NTRK fusions in paediatric or adult patients

Indication: For the treatment of NTRK fusion-positive advanced or recurrent solid tumours in adult patients and paediatric patients aged ≥12 years old

6

Page 22: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Wheretogo?

IdentificationofNTRKfusionsinpediatricpatients

Treatment:when?howlong?

Toxicityandlateeffects

ResistancesandsecondgenerationNTRKi

Page 23: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori
Page 24: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

NointumorwithactivatingmutationmutuallyexclusivetoNTRK

Page 25: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

12

Needforspecific

recommendationsforchildren

Page 26: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Tumourtype Clinicalsummary Screening

methodology Rationale

Infantilefibrosarcoma

•  Mostcommonsofttissuesarcomainchildren<1year•  Morethanhalfofinfantshaveunresectableormetastaticdiseasethatrequiresneoadjuvanttreatment

IHC/FISH(ETV6and/orNTRK3)RT-PCR;NGSifnegative

HighfrequencyofETV6-NTRK3fusion;variantNTRK3andNTRK1fusionshavebeendescribed

Cellularcongenitalmesoblasticnephroma

•  Mostcommonkidneytumourinthefirstmonthoflife•  96%overallsurvivalrate•  Mostpatientstreatedwithnephrectomy;~20%treatedwithadjuvantchemotherapy

IHC/FISH(ETV6and/orNTRK3)RT-PCR;NGSifnegative

HighfrequencyofETV6-NTRK3fusion;variantNTRK3andNTRK1fusionshavebeendescribed

Secretorybreastcancer

•  Raresubtypeofbreastcancer(<0.02%ofpatients)•  Prognosisgenerallygoodwhendiseaseislocalised•  Standardtreatmentissurgerywith/withoutradiation•  Lymphnodemetastasescanoccur,somepatientswithmetastaticrecurrence

IHC/FISH(ETV6and/orNTRK3)RT-PCR;NGSifnegative

HighfrequencyofNTRK3fusions

MASCofthesalivarygland

•  Histologicallyresemblessecretorybreastcancer•  Primarilyoccursinadults;somecasesinadolescents•  AlmostalltumoursharbourETV6-NTRK3fusions

IHC/FISH(ETV6and/orNTRK3)RT-PCR;NGSifnegative

HighfrequencyofNTRK3fusions

Tumourswithhigh-frequencyTRKfusions(>75%)

Page 27: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Tumourswithmedium-frequencyTRKfusions(10%to40%)Tumourtype Clinicalsummary Screening

methodology Rationale

Spitzoidmelanomas

•  Raremelanocyticlesions(rangingfrombenigntomalignantspitzoidmelanoma)

•  90%ofpatientsdiagnosedare<30yearsold•  Childrenaged10–18yearsareatgreaterriskofmetastaticspreadanddeathvsyoungerchildren

•  Recently,recurrentkinasefusionshavebeendescribed

IHC/NGS

TRKfusionsoccurin15–25%ofpaediatricmelanocyticneoplasms

Papillarythyroidcancer

•  Thyroidcancersaccountfor~4%ofmalignanciesinchildren;>90%ofthesearePTCcases

•  Goodprognosis,with>95%overallsurvivalrateat5years•  Treatmentconsistsofthyroidectomyforlocalisedtumours,andradioactiveiodineformetastatictumours

•  TRKfusionsmaybeassociatedwithhigher-stagedisease

IHC/NGS

TRKfusions(NTRK1andNTRK3)occurinapproximately25%ofchildren,andBRAFactivatingmutationsoccurin~50%ofpatients

High-gradegliomas,especiallyinyoungchildren

•  Gliomasarethemostcommonbraintumoursinchildren•  Poorsurvivaloutcomesinchildrenwithhigh-gradegliomas(<25%3-yearoverallsurvivalrate)

•  NTRKfusionsshowntooccurin~40%ofhigh-gradegliomasinchildren<3yearsold

NGS

TRKfusionsoccur,especiallyintumoursofchildren<3yearsofage;patientshavepoorprognosis;IHChasnotbeenvalidatedingliomas,whichcanhavenormalphysiologicexpressionsofTRK

Page 28: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Tumourswithunknownorlow-frequencyTRKfusions(<5%)Tumourtype Clinicalsummary Screening

methodology Rationale

Undifferentiatedsarcoma

(withoutknowndefiningfusion)

•  LinkwithTRKfusionslargelyanecdotal,sofrequencyhasnotbeenestimated

•  Historically,treatmentofundifferentiatedsarcomahasbeenvariable,morerecentlyrisk-basedchemoradiotherapy

NGS

PrevalenceofTRKfusionsunknownbutdescribed;inadditiontoNTRK,othertargetablefusionshavebeendescribed

InflammatoryMyofibroblastic

Tumour

•  Locallyaggressiveneoplasms•  Medianageatdiagnosis:9years•  Metastasesarerare(<5%),andcompletesurgicalresectionisusuallycurative

•  PatientswithALKfusions(50–60%ofcases)haveagoodtreatmentresponsewithcrizotinib

NGS

TRKfusiontumoursmayshareinflammatorymyofibroblastictumour-likemorphology;mutuallyexclusivefusionsofALKandROS1alsooccur

Page 29: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

ICH: sensitivityandspecificityishighinmesenchymaltumorsuselessinbraintumors

SIOPENTRKtestingworkshop

Page 30: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Molecularprofilingprogramsatrelapse

Page 31: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

MYCKIDSTUDY:MOLECULARIDENTITYCARDFORKIDS,ADOLESCENTANDYOUNGADULT

WITHNONRHABDOMYOSARCOMASSOFTTISSUESARCOMA

Page 32: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

EpSSGCountryA

EpSSGCountryB

Center1Localpathology

Center2Localpathology

Center3Localpathology

Center4Localpathology

Utrecht

Frozenmaterial(molecularcharacterization):-  Wholeexomesequencing(WES),RNAseqfor

fusiondetection,DNAmethylation-  Ancillarystudies(organoids,singlecellRNS

sequencing)

Lyon

FFPEmaterial(molecularcharacterization):-  RNAseq,CGH:CINSARC,GI-  Transcriptfusion,clustering:diagnosis

EpSSGCountryC

Diagnosispurpose Researchpurpose

Page 33: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Additionaldataarecominginthenextyearsinadultsandchildren

Page 34: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

LarotrectinibinTreatingPatientsWithPreviouslyUntreatedTRKFusionSolidTumorsandTRKFusion

RelapsedAcuteLeukemia–COGADVL1823

•  PrimaryoutcomemeasureORRofchildrenwithinfantilefibrosarcoma(IFS)treatedwith

neoadjuvantlarotrectinibpriortolocalcontrol

•  SecondaryoutcomemeasuresEFS/OS/DoRinIFStreatedwithneoadjuvantlarotrectinibORR/EFS/OS/DoRinnewlydiagnosedTRKfusionsolidtumorsotherthanIFStreatedwithneoadjuvantlarotrectinibpriortolocalcontrol

IncidenceofadverseeventsPercentageofpatientswithTRKfusionsolidtumorswithdetectablectDNA

Page 35: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Chemotherapy Larotrectinib

EV(catheter) Oral

Effective(75%) Effective(>90%),rapidresponse

Acutetoxicity(VOD) Nosevereacutetoxicity

Durationoftherapy:median4months

Durationoftherapy?

Longtermtoxicityonlytosecondlinetherapy(alkylatingagents,anthracycline)

Longtermeffects?

Costs:cheap Cost:veryexpensive

Available Currentavailabilityonlywithintrials

ChemotherapyversusLarotrectinibasfirst-linetherapyinIFS

Page 36: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

DOXO,doxorubicin;ETV6,translocation-Ets-leukaemiavirus;IFS,infantilefibrosarcoma;IFO,ifosfamide;NTRK,neurotrophictyrosinereceptorkinase;VA,vincristine-actinomycin-D1.InfantileFibrosarcomaConsensusRecommendations.ExPO-r-NetProject.2017;2.MarchiòC,etal.AnnOncol.2019;30:1417–27

Newtargetedtherapies

TheuseofTRKinhibitordrugsshouldbecertainlyconsideredwhenconventionalchemotherapyfails

VAregimenrecommendedinitially

IfresponsetoVAisnotsufficienttopermitconservativesurgery,ifosfamideand/orcyclophosphamideand/ordoxorubicinshouldbeadded

IfnoresponsetoVA,theIFO-DOXOregimenshouldbeadopted

TumourassessmentResectabilitywithoutanyfunctionalormutilatingconsequenceswith

ROintent

Yes:Surgeryfirst

No:Neoadjuvantchemotherapyuntilmaximumtumourshrinkage

IRSI–II:nofurthertherapy

IRSIII:chemotherapy Conservativesurgery

RO,R1margins,completenecrosis:nofurthertherapy

R2:post-operativechemotherapy

EpSSG/EXPeRTguidelinesforIFSrecommendconservativesurgeryorneoadjuvantchemotherapyas

first-linetherapy

Page 37: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

ToxicityandlateaffectsNeurocognitiveoutcome

-Veryyoungchildren-Patientswhoremainontreatmentforyears

DiscussionwithparentsonthistopicisessentialMultipleinitiativeBrussels5thFeb:Readdressingtheneedforlong-termfollowupAccelerategroup:DanielleHortonTaylor/MarkKieran

Page 38: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

Acquiredresistancemechanisms

ResistancetoNTRKinhibitionbylarotrectinibandentrectinibismediatedbyrecurrentmutationstothekinasedomainofNTRKgeneatthreedifferentlocations(solvent-frontmutations,gatekeeperandxDFG)Thekinasesolvent-frontmutationismediatedtroughG595RsubstitutionintheTRKAproteinandG623RsubstitutionintheTRKCproteinThegatekeepermutationisfoundatF589LsubstitutionintheTRKAThexDFGmotifmutationisfoundatG667CsubstitutionintheTRKAproteinandG696SsubstitutionintheTRKCprotein

Page 39: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

SecondgenerationNTRKinhibitorsarebeingdevelopedtoovercomeacquiredresistance

Page 40: NTRK inhibitors: what we learned and where to go · 2020-02-19 · NTRK inhibitors: what we learned and where to go Michela Casanova, Fondazione IRCCS Istituto Nazionale dei Tumori

[email protected]

Thankyou


Other Driver Mutations: cMET, B-RAF, RET, NTRK...Other Driver Mutations: cMET, B-RAF, RET, NTRK. Luis E. RaezMD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial

Other Driver Mutations: cMET, B-RAF, RET, NTRK...Other Driver Mutations: cMET, B-RAF, RET, NTRK. Luis E. RaezMD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial

NTRK Gene Fusion Testing Clinical Guidance Document

NTRK Gene Fusion Testing Clinical Guidance Document

Entrectinib for treating NTRK fusion-positive solid tumours

Entrectinib for treating NTRK fusion-positive solid tumours

PCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS…extranet.provhealth.org/extranet/cardio/Presentations/Are these... · pcsk9 inhibitors, arnis, funny channel inhibitors: are you

PCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS…extranet.provhealth.org/extranet/cardio/Presentations/Are these... · pcsk9 inhibitors, arnis, funny channel inhibitors: are you

Inquiry Inhibitors

Inquiry Inhibitors

Topic 8-2 Other Antibiotics · Protein synthesis inhibitors. Protein synthesis translation inhibitors. Protein synthesis translation inhibitors. Protein synthesis translation inhibitors

Topic 8-2 Other Antibiotics · Protein synthesis inhibitors. Protein synthesis translation inhibitors. Protein synthesis translation inhibitors. Protein synthesis translation inhibitors

Quorum sensing inhibitors Quorum sensing inhibitors … · Quorum sensing inhibitors Quorum sensing inhibitors ... Dunnet test TRI FUR1 FUR2 ... AAII--2 system both Gram2 system both

Quorum sensing inhibitors Quorum sensing inhibitors … · Quorum sensing inhibitors Quorum sensing inhibitors ... Dunnet test TRI FUR1 FUR2 ... AAII--2 system both Gram2 system both

Open Access Review NTRK gene fusions as novel … · NTRK gene fusions as novel targets of cancer therapy across multiple tumour types Alessio Amatu,1 Andrea Sartore-Bianchi,1 Salvatore

Open Access Review NTRK gene fusions as novel … · NTRK gene fusions as novel targets of cancer therapy across multiple tumour types Alessio Amatu,1 Andrea Sartore-Bianchi,1 Salvatore

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From … · 2016-04-18 · SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study Diabetes

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From … · 2016-04-18 · SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study Diabetes

Kinase Inhibitors

Kinase Inhibitors

Cancers digestifs NTRK réarrangés –Larotrectinib

Cancers digestifs NTRK réarrangés –Larotrectinib

TRPM2 Inhibitors

TRPM2 Inhibitors

Microtubule inhibitors. Microtubules Inhibitors Microtubules Inhibitors These drugs disrupt microtubules, which are structures that pull the cell apart.

Microtubule inhibitors. Microtubules Inhibitors Microtubules Inhibitors These drugs disrupt microtubules, which are structures that pull the cell apart.

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance ...Small Molecule Therapeutics PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance ...Small Molecule Therapeutics PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant

CORROSION INHIBITORS. Inhibitors (a)anodic inhibitors: phosphates silicate compounds (b)Cathodic inhibitors poly-phosphates Ca(HCO3)2 methylamino-phosphate.

CORROSION INHIBITORS. Inhibitors (a)anodic inhibitors: phosphates silicate compounds (b)Cathodic inhibitors poly-phosphates Ca(HCO3)2 methylamino-phosphate.

PCSK9 Inhibitors

PCSK9 Inhibitors

Phosphodiesterase inhibitors

Phosphodiesterase inhibitors

Phosphodiesterase inhibitors

Phosphodiesterase inhibitors

ESMO ADVANCED COURSE ON NTRK GENE FUSION · Modifiedfrom Cocco E et al, CancerRes 2019. IHC => For tumours with only weak cytoplasmic expression of pan-TRK, an NTRK fusion should

ESMO ADVANCED COURSE ON NTRK GENE FUSION · Modifiedfrom Cocco E et al, CancerRes 2019. IHC => For tumours with only weak cytoplasmic expression of pan-TRK, an NTRK fusion should

BET bromodomain inhibitors synergize with ATR inhibitors to …download.xuebalib.com/1o2lwAdY4rQg.pdf · ORIGINAL ARTICLE BET bromodomain inhibitors synergize with ATR inhibitors

BET bromodomain inhibitors synergize with ATR inhibitors to …download.xuebalib.com/1o2lwAdY4rQg.pdf · ORIGINAL ARTICLE BET bromodomain inhibitors synergize with ATR inhibitors